Tags

Type your tag names separated by a space and hit enter

Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex.
Pol J Pharmacol. 1993 Sep-Dec; 45(5-6):467-80.PJ

Abstract

Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex, was studied in male Albino-Swiss mice. SL 82.0715, in doses which given alone were inactive in electroshock-induced seizures, potentiated the anticonvulsant effects of CGP 37849. In normal mice, SL 82.0715 decreased the spontaneous locomotor activity, did not affect the locomotor hyperactivity induced by MK-801 and attenuated CGP 37849-induced locomotor hyperactivity. The D-amphetamine locomotor hyperactivity was also antagonized by SL 82.0715. SL 82.0715 did not significantly change the locomotor activity in monoamine-depleted mice (treated with reserpine + alpha-methyl-p-tyrosine). When administered together with clonidine, SL 82.0715 increased the locomotor activity in monoamine-depleted mice but this effect did not reach the level of statistical significance. SL 82.0715 did not change the locomotor activity induced by joint administration of clonidine and MK-801 or clonidine and CGP 37849, in monoamine-depleted mice. The locomotor hyperactivity evoked by L-DOPA (given jointly with benserazide) was not changed by SL 82.0715. SL 82.0715 had no effect on fluphenazine- and haloperidol-induced catalepsy in mice. CGP 37849 attenuated catalepsy induced by haloperidol; that effect was not changed by SL 82.075. The studied compound did not affect the immobility time and had no effect on the action of MK-801 or CGP 37849 in the forced swimming test. The obtained results indicate that SL 82.0715 has a different pharmacological profile than other NMDA antagonists (at least MK-801 and CGP 37849). SL 82.0715 does not increase behavioral actions of MK-801 and CGP 37849, potentiating anticonvulsant effect of CGP 37849 only.

Authors+Show Affiliations

Institute of Pharmacology, Polish Academy of Sciences, Kraków.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7912135

Citation

Dereń-Wesołek, A, and J Maj. "Central Effects of SL 82.0715, an Antagonist of Polyamine Site of the NMDA Receptor Complex." Polish Journal of Pharmacology, vol. 45, no. 5-6, 1993, pp. 467-80.
Dereń-Wesołek A, Maj J. Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex. Pol J Pharmacol. 1993;45(5-6):467-80.
Dereń-Wesołek, A., & Maj, J. (1993). Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex. Polish Journal of Pharmacology, 45(5-6), 467-80.
Dereń-Wesołek A, Maj J. Central Effects of SL 82.0715, an Antagonist of Polyamine Site of the NMDA Receptor Complex. Pol J Pharmacol. 1993 Sep-Dec;45(5-6):467-80. PubMed PMID: 7912135.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex. AU - Dereń-Wesołek,A, AU - Maj,J, PY - 1993/9/1/pubmed PY - 1993/9/1/medline PY - 1993/9/1/entrez SP - 467 EP - 80 JF - Polish journal of pharmacology JO - Pol J Pharmacol VL - 45 IS - 5-6 N2 - Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex, was studied in male Albino-Swiss mice. SL 82.0715, in doses which given alone were inactive in electroshock-induced seizures, potentiated the anticonvulsant effects of CGP 37849. In normal mice, SL 82.0715 decreased the spontaneous locomotor activity, did not affect the locomotor hyperactivity induced by MK-801 and attenuated CGP 37849-induced locomotor hyperactivity. The D-amphetamine locomotor hyperactivity was also antagonized by SL 82.0715. SL 82.0715 did not significantly change the locomotor activity in monoamine-depleted mice (treated with reserpine + alpha-methyl-p-tyrosine). When administered together with clonidine, SL 82.0715 increased the locomotor activity in monoamine-depleted mice but this effect did not reach the level of statistical significance. SL 82.0715 did not change the locomotor activity induced by joint administration of clonidine and MK-801 or clonidine and CGP 37849, in monoamine-depleted mice. The locomotor hyperactivity evoked by L-DOPA (given jointly with benserazide) was not changed by SL 82.0715. SL 82.0715 had no effect on fluphenazine- and haloperidol-induced catalepsy in mice. CGP 37849 attenuated catalepsy induced by haloperidol; that effect was not changed by SL 82.075. The studied compound did not affect the immobility time and had no effect on the action of MK-801 or CGP 37849 in the forced swimming test. The obtained results indicate that SL 82.0715 has a different pharmacological profile than other NMDA antagonists (at least MK-801 and CGP 37849). SL 82.0715 does not increase behavioral actions of MK-801 and CGP 37849, potentiating anticonvulsant effect of CGP 37849 only. SN - 1230-6002 UR - https://www.unboundmedicine.com/medline/citation/7912135/Central_effects_of_SL_82_0715_an_antagonist_of_polyamine_site_of_the_NMDA_receptor_complex_ DB - PRIME DP - Unbound Medicine ER -